[go: up one dir, main page]

AR081407A1 - Toxina clostridiana que comprende un sitio de clivaje de inactivacion y gen quimerico de la misma - Google Patents

Toxina clostridiana que comprende un sitio de clivaje de inactivacion y gen quimerico de la misma

Info

Publication number
AR081407A1
AR081407A1 ARP110101742A ARP110101742A AR081407A1 AR 081407 A1 AR081407 A1 AR 081407A1 AR P110101742 A ARP110101742 A AR P110101742A AR P110101742 A ARP110101742 A AR P110101742A AR 081407 A1 AR081407 A1 AR 081407A1
Authority
AR
Argentina
Prior art keywords
site
toxin
clostridian
inactivation
cliving
Prior art date
Application number
ARP110101742A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR081407A1 publication Critical patent/AR081407A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Toxina clostridiana que comprende al menos un sitio de clivaje de inactivacion ubicado dentro de una region de sitio de clivaje de inactivacion, donde la region de sitio de clivaje de inactivacion se encuentra ubicada en el dominio de translocacion y/o en el subdominio de union HCN, donde el al menos un sitio de clivaje de inactivacion comprende un sitio dual de Trombina-Trombina, un sitio de factor Xa, un sitio de factor dual de Xa-Trombina y/o un sitio MMP-9 y quimérico de toxina clostridiana que comprende un dominio enzimático de dicha toxina clostridíana. Se describen moléculas de polinucleotidos que los codifican, composiciones que los comprenden y método para producirlos.
ARP110101742A 2010-05-20 2011-05-20 Toxina clostridiana que comprende un sitio de clivaje de inactivacion y gen quimerico de la misma AR081407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34657810P 2010-05-20 2010-05-20

Publications (1)

Publication Number Publication Date
AR081407A1 true AR081407A1 (es) 2012-08-29

Family

ID=44484018

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101742A AR081407A1 (es) 2010-05-20 2011-05-20 Toxina clostridiana que comprende un sitio de clivaje de inactivacion y gen quimerico de la misma

Country Status (20)

Country Link
US (13) US8512992B2 (es)
EP (3) EP2571509B1 (es)
JP (4) JP6148979B2 (es)
KR (4) KR101942106B1 (es)
CN (1) CN103228286B (es)
AR (1) AR081407A1 (es)
AU (1) AU2011255525B2 (es)
BR (1) BR112012029666A2 (es)
CA (1) CA2799969C (es)
DK (3) DK2571509T3 (es)
ES (3) ES2813650T3 (es)
IL (1) IL223100B (es)
MX (2) MX369263B (es)
NZ (2) NZ703378A (es)
RU (1) RU2561465C2 (es)
SG (2) SG185663A1 (es)
TW (1) TWI516594B (es)
UA (1) UA108646C2 (es)
WO (1) WO2011146704A1 (es)
ZA (1) ZA201208753B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2750371B2 (ja) 1989-05-12 1998-05-13 触媒化成工業株式会社 接触分解用触媒組成物およびそれを使用した重質炭化水素油の接触分解方法
RU2561465C2 (ru) * 2010-05-20 2015-08-27 Аллерган, Инк. Разрушаемые клостридиальные токсины
EP2773366B1 (en) * 2011-11-04 2017-03-01 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
EP2798077A2 (en) 2011-12-31 2014-11-05 Allergan, Inc. Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
MX369862B (es) 2012-02-15 2019-11-25 Bioverativ Therapeutics Inc Composiciones del factor viii y metodos para hacerlas y usarlas.
EP2861732B1 (en) * 2012-05-30 2019-06-19 The University of Utah Research Foundation Matrix metalloproteinase cleavable protein polymers for cancer gene therapy
RS59876B1 (sr) 2012-07-11 2020-03-31 Bioverativ Therapeutics Inc Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
WO2014100019A1 (en) 2012-12-18 2014-06-26 Allergan, Inc. Prophylactic treatment of herpes recurrence
CN104212833A (zh) * 2013-05-30 2014-12-17 江苏大学 一种新型转基因质粒载体及其构建方法、体内含新型重组基因家蚕的培育方法
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
US20150087810A1 (en) 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
PT4176894T (pt) 2014-01-10 2024-05-21 Bioverativ Therapeutics Inc Proteínas quiméricas de fator viii e utilizações destas
EP3628328B1 (en) * 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
DK3137053T3 (da) 2014-04-30 2020-09-07 Allergan Inc Formuleringer af biologiske lægemidler til intravesikal instillation
US20160030570A1 (en) 2014-07-31 2016-02-04 Allergan, Inc. Formulations of biologics for intravesical instillation
RU2585494C2 (ru) * 2014-09-17 2016-05-27 Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России Рекомбинантный белок rec-mp, содержащий в своем составе последовательности миелопептидов для лечения вторичных иммунодефицитных состояний
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
GB201505306D0 (en) * 2015-03-27 2015-05-13 Ipsen Biopharm Ltd Chimeric polypeptides
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
PL3481852T3 (pl) * 2016-07-08 2023-07-24 Children's Medical Center Corporation Nowa neurotoksyna botulinowa i jej pochodne
CN110072880B (zh) 2016-08-24 2025-02-18 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素
WO2018053111A1 (en) 2016-09-15 2018-03-22 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US10849914B2 (en) 2017-06-12 2020-12-01 University Of Utah Research Foundation Methods for producing chemoembolic agents for the delivery of anti-cancer agents
AU2018314269B2 (en) * 2017-08-11 2022-12-08 University Of Kentucky Research Foundation Anti-neurodegenerative therapeutic, method of manufacture, and use
AU2018389121A1 (en) 2017-12-20 2020-07-30 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders
EP3752128B1 (de) * 2018-02-16 2025-01-15 preclinics discovery GmbH Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
US12049505B2 (en) 2018-12-06 2024-07-30 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
GB202104294D0 (en) * 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
US12077607B2 (en) 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G
KR102728382B1 (ko) * 2022-10-12 2024-11-14 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체
KR20250122877A (ko) * 2024-02-07 2025-08-14 주식회사 알케미어 보툴리눔 독소 e형의 경쇄 변이체

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3949711B2 (ja) 1990-02-26 2007-07-25 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 昆虫ステロイドレセプターｄｎａ配列の同定及び発現
EP0745121B1 (en) 1992-05-14 2007-06-20 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US20090018081A1 (en) 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
KR100876060B1 (ko) 1999-08-25 2008-12-26 알러간, 인코포레이티드 활성화가능한 재조합 신경독
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20030219462A1 (en) 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
JP4262072B2 (ja) 2003-12-05 2009-05-13 株式会社日立製作所 自動車用補助機器制御装置
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
EP1784420B1 (en) * 2004-09-01 2008-12-03 Allergan, Inc. Degradable clostridial toxins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8052979B2 (en) 2005-03-15 2011-11-08 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
ATE463506T1 (de) * 2005-09-19 2010-04-15 Allergan Inc Mit clostriedientoxin aktivierbare clostridientoxine
CA2601537A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP1834962A1 (de) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
EP2038299A2 (en) 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
CA2658260A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
JP2010500967A (ja) * 2006-07-20 2010-01-14 ザ ジェネラル ホスピタル コーポレイション コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット
US7692222B2 (en) 2006-11-07 2010-04-06 Raytheon Company Atomic layer deposition in the formation of gate structures for III-V semiconductor
EP2211890A1 (en) * 2007-10-23 2010-08-04 Allergan, Inc. Methods of treating urogenital-neurological disorders using modified clostridial toxins
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
RU2561465C2 (ru) * 2010-05-20 2015-08-27 Аллерган, Инк. Разрушаемые клостридиальные токсины

Also Published As

Publication number Publication date
US9850476B2 (en) 2017-12-26
US20130330806A1 (en) 2013-12-12
BR112012029666A2 (pt) 2020-10-06
SG10201506567UA (en) 2015-10-29
US20140227740A1 (en) 2014-08-14
US20130330807A1 (en) 2013-12-12
EP2571509B1 (en) 2016-07-06
DK2571509T3 (en) 2016-10-24
US20130273633A1 (en) 2013-10-17
CN103228286A (zh) 2013-07-31
US10501731B2 (en) 2019-12-10
TWI516594B (zh) 2016-01-11
DK3106170T3 (da) 2020-07-13
KR20200118234A (ko) 2020-10-14
US9279116B2 (en) 2016-03-08
CN103228286B (zh) 2018-01-02
EP2650003A1 (en) 2013-10-16
KR20210132753A (ko) 2021-11-04
MX2012013381A (es) 2013-02-21
EP2571509A1 (en) 2013-03-27
JP6644177B2 (ja) 2020-02-12
US8685693B2 (en) 2014-04-01
KR102164166B1 (ko) 2020-10-13
ZA201208753B (en) 2013-09-25
JP2013529213A (ja) 2013-07-18
NZ604322A (en) 2015-01-30
US8697413B2 (en) 2014-04-15
JP2019088296A (ja) 2019-06-13
SG185663A1 (en) 2012-12-28
US20110287517A1 (en) 2011-11-24
KR101942106B1 (ko) 2019-01-25
US9297003B2 (en) 2016-03-29
IL223100A0 (en) 2013-02-03
JP6148979B2 (ja) 2017-06-14
JP6220830B2 (ja) 2017-10-25
US20140127783A1 (en) 2014-05-08
ES2596128T3 (es) 2017-01-05
US9284545B2 (en) 2016-03-15
US8697414B2 (en) 2014-04-15
US8685692B2 (en) 2014-04-01
EP3106170B1 (en) 2020-04-08
US20240018500A1 (en) 2024-01-18
CA2799969C (en) 2019-06-25
US20130288334A1 (en) 2013-10-31
ES2600463T3 (es) 2017-02-09
US20180119126A1 (en) 2018-05-03
WO2011146704A1 (en) 2011-11-24
EP3106170A1 (en) 2016-12-21
DK2650003T3 (da) 2016-11-28
KR20190010720A (ko) 2019-01-30
US20200190496A1 (en) 2020-06-18
MX369263B (es) 2019-11-04
EP2650003B1 (en) 2016-07-27
KR102321664B1 (ko) 2021-11-04
RU2561465C2 (ru) 2015-08-27
US20130196414A1 (en) 2013-08-01
JP2015193669A (ja) 2015-11-05
IL223100B (en) 2018-02-28
JP2018012696A (ja) 2018-01-25
HK1180592A1 (zh) 2013-10-25
US8841111B2 (en) 2014-09-23
CA2799969A1 (en) 2011-11-24
AU2011255525B2 (en) 2015-09-10
JP6467000B2 (ja) 2019-02-06
TW201142026A (en) 2011-12-01
RU2012154862A (ru) 2014-06-27
UA108646C2 (xx) 2015-05-25
US8512992B2 (en) 2013-08-20
KR20130054967A (ko) 2013-05-27
NZ703378A (en) 2016-10-28
US20140220627A1 (en) 2014-08-07
US20160201046A1 (en) 2016-07-14
ES2813650T3 (es) 2021-03-24
AU2011255525A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
AR081407A1 (es) Toxina clostridiana que comprende un sitio de clivaje de inactivacion y gen quimerico de la misma
CO2019009028A2 (es) Composicion y metodos para digestion mejorada microbiana de polimeros en pozos de fractura
MX2021009886A (es) Enzimas con dominios ruvc.
BR112014012543A2 (pt) métodos e materiais para síntese enzimática de compostos de mogrosídeo
MX342388B (es) Variantes y composiciones que comprenden variantes con alta estabilidad en presencia de un agente quelante.
CL2016000839A1 (es) Composiciones para modular la expresión de c9orf72.
TN2009000521A1 (en) Rnai inhibition of alpha-enac expression
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
MX2009004778A (es) Enzima para la produccion de peracido de cadena larga.
EA201300430A1 (ru) Реагенты для деструкции ферментов и способы их применения в жидкостных системах
BR112012028049A2 (pt) organismo microbiano de ocorrência não natural e método para produzir butadieno, meio de cultura, butadieno biossintetizado, composição, produto químico orgânico, polímero e uso de butadieno biossintetizado
UY32395A (es) Compuesto con anillo fusionado y su uso
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
EA201071270A1 (ru) Разрушающие флюиды высокой плотности и способы их применения
CL2009001082A1 (es) Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86.
BR112012018620A2 (pt) organismo microbiano de ocorrência não-natural, método para produzir (2-hidroxi-3-metil-4-oxobutoxi) fosfonato, método para produção de p-toluato, método para produzir tereftalato
BR112018010691A2 (pt) ?métodos para remover micro-organismos e depósitos minerais e crescimento microbiano?
CR11521A (es) Tratamiento de plantas de platano y papa con una nueva composicion antifungica
UY33624A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse
MX2018001427A (es) Metodos para administrar enzimas o microbios productores de carbonato de calcio en el fondo del pozo.
BR112013010358A2 (pt) composição anticorrosiva do espaçoi de vapor, e, uso de composição anticorrosiva do espaço de vapor
AR105792A2 (es) Método para el tratamiento de biomasa
PE20142111A1 (es) Desactivacion microbial de composiciones explosivas
MX2013006166A (es) Fibras degradables.

Legal Events

Date Code Title Description
FC Refusal